Assignee
SHANGHAI REGENELEAD THERAPIES CO LTD
CN·0 granted patents·4 pending applications·0 citations·filing 2022–2023
Top patents by PatentIndex Score
4 records- 0161US2026008835A1Vegf-binding molecule and pharmaceutical use thereofSHANGHAI REGENELEAD THERAPIES CO LTD·Filed 2023·Application pending·0 cites
- 0259US2025288659A1Nucleic acid construct and use thereofSHANGHAI REGENELEAD THERAPIES CO LTD·Filed 2023·Application pending·0 cites
- 0357US2024252679A1Recombinant adeno-associated virus having variant capsid, and application thereofSHANGHAI REGENELEAD THERAPIES CO LTD·Filed 2022·Application pending·0 cites
- 0456US2025051750A1Aadc/gdnf polynucleotide, and use thereof in treating parkinson's diseaseSHANGHAI REGENELEAD THERAPIES CO LTD·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SHANGHAI REGENELEAD THERAPIES CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →